Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy.

ABSTRACT:

Background

We aim to provide survival scenario estimates for patients with advanced melanoma starting targeted therapies and immunotherapies.

Materials and methods

We sought randomized trials of targeted therapies and immunotherapies for advanced melanoma and recorded the following percentiles (represented survival scenario) from each overall survival (OS) curve: 90th (worst-case), 75th (lower-typical), 50th (median), 25th (upper-typical), and 10th (best-case). We tested whether these scenarios can be estimated for each OS curve by multiplying its median by 4 multiples: 0.25 (worst-case), 0.5 (lower-typical), 2 (upper-typical), and 3 (best-case).

Results

We identified 15 trials with 8025 patients. For first-line combination targeted therapy treatment groups, the media

SUBMITTER: Smith-Uffen M 

PROVIDER: S-EPMC11546645 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature